Stock Track | Relay Therapeutics Plunges 7.69% Post-Market on Q1 EPS Miss and Sharp Revenue Decline

Stock Track05-06

Relay Therapeutics' stock tumbled 7.69% in post-market trading on Tuesday, as investors reacted to the company's first-quarter 2026 financial results.

The clinical-stage precision medicine company reported a quarterly loss of $0.41 per share, which missed the analyst consensus estimate of a $0.37 loss. Revenue for the quarter was $3 million, a 60.9% decrease from the $7.7 million reported in the same period last year, although it surpassed expectations of $2.56 million. The net loss widened to $73.3 million, exceeding the IBES estimate of a $65 million loss.

Despite announcing positive corporate updates, including FDA Breakthrough Therapy designation for its lead drug candidate zovegalisib, the earnings miss and significant year-over-year revenue drop appear to have driven the negative market sentiment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1182622164?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 10:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182622164","market":"sg","top_or_hot":-1,"title":"Stock Track | Relay Therapeutics Plunges 7.69% Post-Market on Q1 EPS Miss and Sharp Revenue Decline","media":"Stock Track","content":"<p>Relay Therapeutics' stock tumbled 7.69% in post-market trading on Tuesday, as investors reacted to the company's first-quarter 2026 financial results.</p><p>The clinical-stage precision medicine company reported a quarterly loss of $0.41 per share, which missed the analyst consensus estimate of a $0.37 loss. Revenue for the quarter was $3 million, a 60.9% decrease from the $7.7 million reported in the same period last year, although it surpassed expectations of $2.56 million. The net loss widened to $73.3 million, exceeding the IBES estimate of a $65 million loss.</p><p>Despite announcing positive corporate updates, including FDA Breakthrough Therapy designation for its lead drug candidate zovegalisib, the earnings miss and significant year-over-year revenue drop appear to have driven the negative market sentiment.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Relay Therapeutics Plunges 7.69% Post-Market on Q1 EPS Miss and Sharp Revenue Decline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Relay Therapeutics Plunges 7.69% Post-Market on Q1 EPS Miss and Sharp Revenue Decline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-06 10:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Relay Therapeutics' stock tumbled 7.69% in post-market trading on Tuesday, as investors reacted to the company's first-quarter 2026 financial results.</p><p>The clinical-stage precision medicine company reported a quarterly loss of $0.41 per share, which missed the analyst consensus estimate of a $0.37 loss. Revenue for the quarter was $3 million, a 60.9% decrease from the $7.7 million reported in the same period last year, although it surpassed expectations of $2.56 million. The net loss widened to $73.3 million, exceeding the IBES estimate of a $65 million loss.</p><p>Despite announcing positive corporate updates, including FDA Breakthrough Therapy designation for its lead drug candidate zovegalisib, the earnings miss and significant year-over-year revenue drop appear to have driven the negative market sentiment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RLAY","symbol_name":"Relay Therapeutics","start_time":0,"source_url":"","article_id":"1182622164","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182622164","pubTimestamp":1778035784,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Relay Therapeutics' stock tumbled 7.69% in post-market trading on Tuesday, as investors reacted to the company's first-quarter 2026 financial results.The clinical-stage precision medicine company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RLAY":"Relay Therapeutics"},"translate_title":"个股追踪|Relay Therapeutics盘后暴跌7.69%，因Q1 EPS未达预期且营收大幅下滑","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RLAY":1},"content_text":"Relay Therapeutics' stock tumbled 7.69% in post-market trading on Tuesday, as investors reacted to the company's first-quarter 2026 financial results.The clinical-stage precision medicine company reported a quarterly loss of $0.41 per share, which missed the analyst consensus estimate of a $0.37 loss. Revenue for the quarter was $3 million, a 60.9% decrease from the $7.7 million reported in the same period last year, although it surpassed expectations of $2.56 million. The net loss widened to $73.3 million, exceeding the IBES estimate of a $65 million loss.Despite announcing positive corporate updates, including FDA Breakthrough Therapy designation for its lead drug candidate zovegalisib, the earnings miss and significant year-over-year revenue drop appear to have driven the negative market sentiment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1182622164","isCrawlerRequest":true}